Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.
Prolaris — a genetic test that predicts the aggressiveness of prostate cancer — can accurately identify which men with intermediate- or high-risk ... Read more
Researchers have developed an artificial intelligence (AI) tool that shows the potential to predict prostate cancer aggressiveness and the likelihood of ... Read more
Provenge (sipuleucel-T), by Dendreon Pharmaceuticals, is superior to Zytiga (abiraterone acetate) or Xtandi (enzalutamide) at prolonging the lives of men with ... Read more
Lynparza (olaparib) has been recommended for approval in the European Union to treat men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations ... Read more
Cryotherapy directed to the cancerous part of the prostate may be an effective and less invasive treatment option for men with intermediate-risk, ... Read more
Adding Xtandi (enzalutamide) to standard androgen deprivation therapy (ADT) significantly prolonged life by nearly a year for men with high-risk, non-metastatic ... Read more
Combining two methods of prostate biopsy — using one guided by magnetic resonance imaging (MRI) along with conventional ultrasound-guided biopsy — ... Read more
